- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer introduces next-generation digital mammography system
The SenoScan2 slot scanning digital mammography (SSDM) system from Fischer Imaging is being introduced at the RSNA meeting. Fischer designs, manufactures, and markets medical imaging systems for screening and diagnosis.
The SenoScan2 slot scanning digital mammography (SSDM) system from Fischer Imaging is being introduced at the RSNA meeting. Fischer designs, manufactures, and markets medical imaging systems for screening and diagnosis.
The system mixes high image resolution and reduced radiation dose, while virtually eliminating motion artifacts, according to the company. Fischer calls it the next generation of slot scanning technology and claims SenoScan2 is the only digital mammography unit to offer both 50- and 25-micron native diagnostic resolution.
SenoScan2 will be included in a three-year global agreement signed last month with Philips Medical Systems. Under terms of the agreement, Philips will sell, service, and support a specialized version of Fischer's digital mammography system integrated with Philips' image processing and user interface.
"The SenoScan2 enables users to fully maximize image quality with customizable workflow and image management capabilities in a series of robust workstations that will scale to their needs," said Harris Ravine, president and CEO of Fischer. "The partnership with Philips will dramatically expand access to powerful end-to-end digital mammography solutions."
Fischer's slot scanning technology uses a tightly collimated x-ray beam that scans in precise alignment with a narrow slotted image receptor. The design essentially eliminates the negative effects of scatter radiation without requiring the use of a grid. The result is sharp, high-resolution images with up to a 60% reduction in radiation dose, according to the company.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
